Table 1.
Top 20 proteins that differed in preclinical AD from the control group according to CSF t-tau status
| Contrast | Cohort | Number of proteins that differ | Top 20 proteins with largest effect size |
|---|---|---|---|
| Preclinical AD with increased t-tau | |||
| Proteins with increased concentration relative to CN | EMIF-AD MBD | 262 | YWHAH, LAMP5, PCSK5, CHI3L1, SMOC1, ADCYAP1, SPP1, GDA, CRYM, TAGLN3, PLXNA2, PCDH8, HPRT1, CPD, GAP43, ENPP5, CAMK2A, PKM, MELTF, NAXE |
| ADNI | 93 | NRGN, PKM, VSNL1, GOT1, ALDOA, SPP1, GOT2, HGF, NEO1, NCSTN, MOG, APLP2, SOD1, BACE1, APP, CHI3L1, FABP3, ENO2, NCAM2, SPON1 | |
| Proteins with decreased concentration relative to CN | EMIF-AD MBD | 19 | S100A6, ADAMDEC1, GPLD1, ANXA5, KNG1, SERPINA4, HSPA1A, IGHV4-30–2, CPB2, IGHV4-30–4, FLNA, IGHV3-30, PRAP1, IGLV3-10, HSPA6, ABI3BP, IGHV2-70D, HSPA7, PON1 |
| ADNI | 2 | GOLM1, LEP | |
| Preclinical AD with normal t-tau | |||
| Proteins with increased concentration relative to CN | EMIF-AD MBD | 36 | SLC39A12b, ADIPOQa, ANGPTL7, LGI1b, CD9b, KRT24, IFI30a, TTRb, FOLR1b, NCMAP, SLC5A5b, SELPLG, ENPP2b, F5b, CTSA, KRT12, KRT9, SIAEb, COL15A1, KRT10 |
| ADNI | 3 | EDN1, APOE-e4, FGF4b | |
| Proteins with decreased concentration relative to CN | EMIF-AD MBD | 102 | HS6ST1, CDH9, ASTN1, PLXNA1, APP, PMP2, STMN3, CDH8, PRKAR1A, GABARAPL2, GALNT6, PITHD1, GALNT1, CPM, MMP17, FAM19A2, CD99, FURIN, TAGLN, CDH12 |
| ADNI | 24 | abeta1-40, abeta1-38, ADGRL1, CADM3, NEO1, NPTX1, MCAM, CHGB, PCSK1, NEGR1, L1CAM, UBB, PTPRN, CACNA2D1, TIMP1, PAM, BTD, VEGFA, DAG1, NBL1 | |
T-tau Total tau, CN Control group with normal cognition, normal Aβ1-42 and normal t-tau
aProtein associated with Blood Brain Barrier dysfunction
bProteins with high expression in choroid plexus. Full list of proteins is provided in Data S2, column BK-BN